secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-11-20T23:59:59+00:00
Accession:  0001493152-25-024450
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir-1 kills aggressive human leukemia cells in vitro; expands oncology profile into blood cancers
--------------------------------------------------------------------------------

- Telomir-1 produced dose-dependent reduction in viability of human HL60 leukemia cells (aggressive AML model).
- Leukemia cells depend on intracellular iron; Telomir-1 lowers intracellular Fe²⁺ more potently than DFO.
- Prior research shows Telomir-1 reduces abnormal DNA methylation of tumor-suppressor genes and inhibits KDM histone demethylases.
- Findings add to previously reported activity against triple-negative breast, pancreatic, and prostate cancer models.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225024450/0001493152-25-024450-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315225024450/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-024450

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer